Trastuzumab deruxtecan: observed
41 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast CancerRecruitingNCT07653893Report a problem
- BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine TherapyRecruitingNCT07597993Report a problem
- Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic ResponseRecruitingNCT07582887Report a problem
- A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer PatientsRecruitingNCT07281001Not applicableReport a problem
- Trastuzumab Deruxtecan in Advanced Breast CancerRecruitingNCT07180264Report a problem
- DESTINY-PANTUMOUR04RecruitingNCT07124000Report a problem
- Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXdRecruitingNCT07073755Report a problem
- Mechanisms of Response and Resistance to Innovative Treatments in Patients With Locally Advanced or Metastatic Breast CancerRecruitingNCT07066917Report a problem
- Toxicity Markers to Trastuzumab-Deruxtecan (T-DXd) In Patients With Advanced Breast CancerRecruitingNCT07049133Report a problem
- A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast CancerNot yet recruitingNCT07035353Report a problem
- RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 StudyRecruitingNCT07030569Report a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingNCT07021911Report a problem
- Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in KoreaRecruitingNCT06928818Report a problem
- Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast CancerRecruitingNCT06877416Report a problem
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Report a problem
- HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBCRecruitingNCT06830382Report a problem
- Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)RecruitingNCT06809764Report a problem
- A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric CancerRecruitingNCT06767436Report a problem
- Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast CancerRecruitingNCT06727227Report a problem
- Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression PatternsRecruitingNCT06551220Report a problem
- A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingNCT06210776Report a problem
- Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior PyrotinibRecruitingNCT06135194Report a problem
- DESTINY Breast Respond HER2-(Ultra)Low EuropeRecruitingNCT05945732Report a problem
- PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanRecruitingNCT05573893Report a problem
- Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4RecruitingNCT05088395Not applicableReport a problem
- TDXD in Metastatic HER2-Positive Breast CancerCompletedNCT07778407Report a problem
- Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world StudyCompletedNCT07108595Report a problem
- ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161Report a problem
- Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.CompletedNCT06961331Report a problem
- A ReaL World Study of DS-8201Active, not recruitingNCT06945224Report a problem
- Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab DeruxtecanCompletedNCT06833268Report a problem
- Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 TreatmentActive, not recruitingNCT06663787Report a problem
- Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab GovitecanCompletedNCT06504719Report a problem
- HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in CanadaCompletedNCT06386263Report a problem
- Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in BrazilTerminatedNCT06231693Report a problem
- A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)Active, not recruitingNCT05993234Report a problem
- Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast CancerStatus unknownNCT05594082Report a problem
- EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab DeruxtecanCompletedNCT05458401Report a problem
- Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related ToxicitiesCompletedNCT05349383Report a problem
- Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast CancerCompletedNCT05149014Report a problem
- HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)Active, not recruitingNCT04257162Not applicableReport a problem